<DOC>
	<DOC>NCT01107392</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.</brief_summary>
	<brief_title>Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Clinical enlargement of the prostate gland Body weight ≥ 50 kg or 110 lbs History of chronic prostatitis History of two or more urinary tract infections in the past year or one in the last 6 months History of bladder stones History of previous prostate surgery History of bladder cancer or prostate cancer Any previous or current usage of botulinum toxin therapy of any serotype for any urological condition Botulinum toxin therapy of any serotype for any nonurological condition or usage (e.g., cosmetic) during the previous 12 weeks prior to study entry</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>